“Catalyst HTI’s central location and life science focus is what initially drew us to build a footprint here,” said Charles J Fisher, Jr., MD, CEO of SeaStar. “Coming together here has catalyzed our product development efforts, which have the potential to save lives and set new standards for treating acute organ injuries.”
As a commercial-stage, product driven, medical device company, SeaStar‘s FDA-Cleared device is designed to potentially reduce organ injury in patients and organ donors. Its CLR (Cardiac, Lung & Renal) cartridge is currently being used to improve donor organ function, increasing the number of viable organs for the more than 120,000 patients currently waiting for lifesaving transplants.
SeaStar’s innovative approach to modulating inflammation has led to the development of the Selective Cytopheretic Device (SCD) family of cartridges, which have demonstrated the ability to reduce inflammation and organ failure. The SCD captures activated leukocytes and transforms them from proinflammatory to reparative. This program has the potential to be transformative to the care and management of critically ill patients.
“With my work across healthcare innovation in our nation and beyond, it is becoming more and more evident that digital health, medical device, bio and life science, pharma and other disciplines are converging and integrating with each other. And, I anticipate this convergence and integration to further accelerate in the future. Thus, I’m thrilled to have SeaStar’s mindshare and leadership on campus as we commit to work together to move the health of our nation forward,” proclaimed Mike Biselli, President and Co-Founder of Catalyst HTI.
About SeaStar Medical, Inc.
SeaStar Medical’s transformative Immunomodulating technology, addresses transplantation, inflammation, and oncology. This innovative bedside technology has been shown to be safe in humans and demonstrated reduction of inflammation, and associated tissue injury to vital organs. SeaStar’s name is inspired by the sea star, which possesses both unique anti-inflammatory and anti-cancer properties. For more information, visit www.seastarmedical.com.
About Catalyst HTI
Located in Denver, Colorado’s River North District (RiNo), Catalyst HTI is a 180,000 square-foot industry integrator designed to bring health-tech start-ups and established health care entities together under one roof. The building covers an entire block, located on the west side of Brighton Boulevard between 35th and 36th Streets. Catalyst HTI’s goal is to bring together private enterprise (startups to Fortune 100), government, academic and non-profit organizations with healthcare providers and payers to accelerate innovation and drive real, lasting change. For more information visit www.catalysthealthtech.com.